BioSpace News Archive

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today presented new data on its epigenetic editing platform at Cold Spring Harbor Laboratory’s Genome Engineering: CRISPR Frontiers conference, being held August 16-20, 2023, in Cold Spring Harbor, NY.

As previously announced, on July 16, 2023, MediPacific Sub, Inc. and MediPacific, Inc., affiliates of Foresite Capital, entered into a definitive agreement and plan of merger with Pardes Biosciences, Inc..

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced that it has received the final 510(k) clearance from the FDA for the Integrity™ Implant System.

IMIDEX, a leader in developing AI-based solutions to address lung cancer, announces that it has received FDA 510(k) clearance for its flagship VisiRad XR product.

MediciNova, Inc., today announced that an abstract regarding tumor tissue analysis data from a clinical trial of MN-166 (ibudilast) in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 15 - 19, 2023 in Vancouver, British Columbia, Canada.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”), today announced the European Medicines Agency (EMA) has accepted for regulatory review the marketing authorization application (MAA) for avacincaptad pegol (ACP), an investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Everest Medicines’ (HKEX 1952.HK, “Everest”, or the “Company”) partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced the publication in The Lancet of the full data from the NeflgArd Phase 3 trial with Nefecon® in adults with primary IgA nephropathy (IgAN).

GC Biopharma announced on August 17, 2023 that it has presented the results of analyzing and comparing thrombotic adverse events of Hemlibra and Factor FVIII replacements reported in the US Food and Drug Administration Adverse Event Reporting System at the Bleeding Disorder Conference currently being held in Maryland, U.S. from August 17 to August 19, 2023.

Athersys, Inc., announced the pricing of its “reasonable best efforts” public offering of 10,937,500 shares of common stock at a purchase price of $0.32 per share.

August 16, 2023, at the 2023 World Conference on Lung Cancer (WCLC), the complete list of selected abstracts was announced, among which QiLu Pharmaceutical’s iruplinalkib phase III clinical trial (INSPIRE) results were chosen for oral presentation at the conference.